Gapping up
In reaction to strong earnings/guidance:
- QD +5%, IGT +1.2%
Other news:
- MDCO +12.2% (reports interim results from ongoing ORION-3 study demonstrating sustained lowering of LDL-C by more than 50%)
- QGEN +3.4% (receives 510(k) clearance by FDA for QIAstat-Dx in the US)
- NOK +3% (speculation to be beneficiary of Huawei's supplier losses)
- TAK +2.2% (reports new data from VARSITY study demonstrating superiority of Vedolizumab to Adalimumab in clinical remission at week 52)
- ERIC +1.1% (speculation to be beneficiary of Huawei's supplier losses)
Analyst comments:
- JACK +1.6% (upgraded to Buy from Hold at Stifel)
- LPX +1.6% (upgraded to Buy from Neutral at Longbow)
- GD +0.8% (upgraded to Buy from Neutral at Goldman)